PerceptiMed names new VP sales and marketing
MOUNTAIN VIEW, Calif. — Pharmacy technology company PerceptiMed on Monday announced the appointment of Terry Cater to the position of VP sales and marketing.
“We are pleased that Terry has joined our operation to lead our sales and marketing efforts at this critical time of growth for PerceptiMed,” PerceptiMed founder Dr. Alan Jacobs said, “Terry’s skillsets will help to maximize the pilot programs that we have successfully completed, and to leverage that success in our sales channels as we establish a new industry standard for dispensing medication.”
Cater has worked in the chain drug, supermarket, drug wholesaling and healthcare technology sectors over the course of his career, most recently serving as director of pharmacy at Safeway Pharmacies and Save Mart Stores in California. He has held VP-level positions at Cardinal Health and McKesson, and has operated an independent pharmacy consultancy for 10 years. He is a member of the California Pharmacists Association and belongs to various national organizations, including the National Community Pharmacists Association.
Perceptimed’s offerings, which include medication verification and dispensing technology IdentRx, and will-call solution scripClip, work to reduce dispensing errors in pharmacy.
FDA approves Aurobindo’s Micardis HCT generic
SILVER SPRING, Md. — The Food and Drug Administration has approved Aurobindo’s generic of Micardis HCT (telmisartan and hydrochlorothiazide) tablets, the company announced Friday.
The drug is indicated to treat hypertension and had a market size of $81.9 million for the 12 months ended November 2016, according to QuintilesIMS data.
Aurobindo’s generic will be available in dosage strengths of 40 mg telmistartan/12.5 mg hydrochlorothiazide, 80 mg telmisartan/12.5 mg hydrochlorothiazide and 8- mg telmisartan/25 mg hydrochlorothiazide.
Bristol-Myers Squibb decides against accelerated approval for Opdivo/Yervoy combo for lung cancer
PRINCETON, N.J. — Bristol-Myers Squibb has announced that it will not seek an accelerated regulatory approval for a combination of its Opdivo (nivolumab) and Yervoy (ipilimumab) as a first-line treatment for lung cancer.
The company said the announcement was “based on a review of data available at this time,” and noted that they would not provide additional details to “protect the integrity of ongoing registrational studies.”
The Food and Drug Administration approved the regimen of Opdivo and Yervoy as a treatment for metastatic melanoma in October 2015.
Loading Post Please Wait...